| Delaware | 11-3516358 | |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification Number.) | 
| 8 Davis Drive Durham, NC | 27713 | |
| (Address of principal executive offices) | (Zip code) | 
| Ocuphire Pharma, Inc. 2020 Equity Incentive Plan | 
| (Full title of the plan) | 
| Dr. George Magrath Chief Executive Officer Opus Genetics, Inc. 8 Davis Drive Durham, NC 27713 (984) 884-6030 | 
| (Name, address, and telephone number, including area code, of agent for service) | 
| Large accelerated filer ☐ | Accelerated filer ☐ | 
| Non-accelerated filer ☒ | Smaller reporting company ☒ | 
| Emerging growth company ☐ | 
| Item 3. | Incorporation of Documents By Reference. | 
| (a) | the Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 31, 2025 (the “2024 Annual Report”); | 
| (b) | the Registrant’s Quarterly Reports on Form 10-Q, filed with the Commission on May 15, 2025 and August 13, 2025; | 
| (c) | the Registrant’s Current Reports on Form 8-K, filed with the Commission on January 7, 2025, January 14, 2025, January 23, 2025, January
              24, 2025, March 4, 2025, March 20, 2025, March 24,
              2025, April 4, 2025, May
              1, 2025, June 20, 2025, June 25, 2025, June 26, 2025, July 23, 2025, August 25, 2025, and September 2, 2025; and | 
| (d) | the description of the Registrant’s Common Stock contained in the Registrant’s Form 8-A (File No. 001-34079), as filed with the Commission pursuant to Sections 12(b) and 12(g) of the Securities Exchange Act of
              1934, as amended (the “Exchange Act”), on June 7, 2019, including any amendments or reports filed for the
              purpose of updating such description, including Exhibit 4.12 to the 2024 Annual Report. | 
| Item 8. | Exhibits. | 
| Exhibit Number | Description | 
| Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Quarterly Report on Form 10-Q, filed with the Commission on August 13, 2024). | |
| Certificate of Amendment to the Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K, filed with the Commission on
            October 22, 2024). | |
| Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed with the Commission on March 20, 2025). | |
| Ocuphire Pharma, Inc. 2020 Equity Incentive Plan (incorporated by reference to Annex D to the Registrant’s Registration Statement on Form S-4, filed with the Commission on July 6, 2020). | |
| Opinion of Sidley Austin LLP. | |
| Consent of Ernst & Young LLP. | |
| Consent of Sidley Austin LLP (included in Exhibit 5.1). | |
| Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement). | |
| Filing Fee Table. | 
| * | Filed herewith. | 
| OPUS GENETICS, INC. | |||
| By: | /s/ Dr. George Magrath | ||
| Name: | Dr. George Magrath | ||
| Title: | Chief Executive Officer | ||
| SIGNATURE | TITLE | DATE | ||
| /s/ Dr. George Magrath | ||||
| Dr. George Magrath | Chief Executive Officer & Director (Principal Executive Officer) | September 26, 2025 | ||
| /s/ Robert Gagnon | ||||
| Robert Gagnon | Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) | September 26, 2025 | ||
| /s/ Cam Gallagher | ||||
| Cam Gallagher | Chair of the Board | September 26, 2025 | ||
| /s/ Sean Ainsworth | ||||
| Sean Ainsworth | Director | September 26, 2025 | ||
| /s/ Dr. Jean Bennett | ||||
| Dr. Jean Bennett | Director | September 26, 2025 | ||
| /s/ Susan K. Benton | ||||
| Susan K. Benton | Director | September 26, 2025 | 
| /s/ Dr. Adrienne Graves | ||||
| Dr. Adrienne Graves | Director | September 26, 2025 | ||
| /s/ Dr. James S. Manuso | ||||
| Dr. James S. Manuso | Director | September 26, 2025 | ||
| /s/ Richard J. Rodgers | ||||
| Richard J. Rodgers | Director | September 26, 2025 | ||
| /s/ Dr. Benjamin R. Yerxa | ||||
| Dr. Benjamin R. Yerxa | President and Director | September 26, 2025 |